---
title: "Trientine - Renal cell carcinoma"
sidebar: mydoc_sidebar
permalink: trientinerenalcellcarcinoma3.html
toc: false 
---

{% include image.html url="images/trientinerenalcellcarcinoma3.png" file="trientinerenalcellcarcinoma3.png" alt="trientinerenalcellcarcinoma3" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D014266 | Trientine | Drug |
| REACT:R-HSA-6802957 | Oncogenic MAPK signaling | Pathway |
| MESH:D003300 | Copper | ChemicalSubstance |
| MESH:D000975 | Antioxidants | ChemicalSubstance |
| GO:0012501 | Apoptosis | BiologicalProcess |
| CL:0001063 | Tumor cell | Cell |
| MESH:D002292 | Renal cell carcinoma | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Trientine | NEGATIVELY REGULATES | Oncogenic Mapk Signaling |
| Oncogenic Mapk Signaling | CAUSES | Apoptosis |
| Trientine | MOLECULARLY INTERACTS WITH | Copper |
| Copper | INCREASES ABUNDANCE OF | Antioxidants |
| Antioxidants | CAUSES | Apoptosis |
| Apoptosis | LOCATED IN | Tumor Cell |
| Tumor Cell | CAUSES | Renal Cell Carcinoma |
|---------|-----------|---------|

Comment: Trientine is the salt form of Triethylenetetramine (DB06824)

Reference: [https://go.drugbank.com/drugs/DB06824#mechanism-of-action](https://go.drugbank.com/drugs/DB06824#mechanism-of-action){:target="_blank"}